Alzheimer disease (AD) is the most common contributor to dementia in the world, but
strategies that slow or prevent its clinical progression have largely remained elusive, until …

Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …

As the number of patients with Alzheimer's disease (AD) increases, it brings great suffering
to their families and causes a heavy socioeconomic burden to society. A vast amount of …

ApoE is the major lipid and cholesterol carrier in the CNS. There are three major human
polymorphisms, apoE2, apoE3, and apoE4, and the genetic expression of APOE4 is one of …

Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …

Astrocytes contribute to the complex cellular pathology of Alzheimer's disease (AD).
Neurons and astrocytes function in close collaboration through neurotransmitter recycling …

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss
and personality changes, eventually leading to dementia. The pathological hallmarks of AD …

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive
memory loss along with neuropsychiatric symptoms and a decline in activities of daily life. Its …

Alzheimer's disease (AD) is highly heritable and recent studies have identified over 20
disease-associated genomic loci. Yet these only explain a small proportion of the genetic …

Alzheimer's disease is a neurodegenerative disease that accounts for most of the 50-million
dementia cases worldwide in 2018. A large amount of evidence supports the amyloid …